cemiplimab
1 clinical trial
18 products
42 abstracts
1 indication
Indication
Cutaneous Squamous Cell CarcinomaAbstract
Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).Org: Gustave Roussy Cancer Center, The Institute of Cancer Research/The Royal Marsden Hospital, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research, ISA Pharmaceuticals B.V., Regeneron Pharmaceuticals, Inc.,
Abstract
Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.Org: University of Chicago Medicine, University of Chicago, University of California, San Francisco Department of Medicine, University of California, San Francisco Department of Surgery, University of California, San Francisco,
Abstract
Trends in prices of checkpoint inhibitors in the US, 2016-2023.Org: Brigham and Women's Hospital, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center,
Abstract
A phase 1 dose-escalation and expansion study of an intratumorally administered dual STING agonist (ONM-501) alone and in combination with cemiplimab in patients with advanced solid tumors and lymphomas.Org: University of Pittsburgh Medical Center (UPMC), The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, UPMC Hillman Cancer Center, UT Southwestern Medical Center, OncoNano Medicine Inc.,
Abstract
A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer.Org: Lyon University Hospital, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), EPSILYON, Université Claude Bernard Lyon 1, Gustave Roussy, Département de Médecine Oncologique, Peter MacCallum Cancer Centre, University of Melbourne, Prince of Wales Hospital and University of New South Wales,
Abstract
A phase 2, multicenter, open-label, dose-optimization study evaluating telomere-targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Updated results.Org: Medical University in Lublin, Lublin, Szolnok, Hungary, Matrai Gyogyintezet,
Abstract
CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma.Org: Brown University/Lifespan Cancer Institute,
Abstract
PD-1 checkpoint inhibitors related immune-mediated hepatitis in colon cancer: A systematic review and meta-analysis.Org: New York Medical College - Saint Michael's Medical Center, Landmark Medical Center,
Abstract
Combination of cemiplimab and ISA101b vaccine for the treatment of recurrent/metastatic HPV16 cervical cancer.Org: Catholic University of Rome, Clínica de Neoplasias Litoral, University Hospital of Leuven, Leuven Cancer Institute, Barretos Cancer Hospital,
Abstract
A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.Org: High Technology Medical Center, University Clinic Ltd., Tbilisi, Georgia, LTD High Technology Hospital Med Center, Batumi, Georgia, JSC Vian Caraps Medline, European University, Tbilisi, Georgia, University of Tennessee Medical Center, Knoxville, TN, Mid Florida Cancer Centers, Orange City, FL,
Abstract
A phase 1 study of fianlimab (anti–LAG-3) in combination with cemiplimab (anti–PD-1) in patients with advanced HNSCC.Org: Zuckerberg Cancer Center, Northwell Health Cancer Institute, Tallaght University Hospital,
Abstract
Primary immunotherapy monotherapy (PRIMO) in locally advanced cutaneous squamous cell carcinoma.Org: Cleveland Clinic Taussig Cancer Instititute, OHB Neonatology,
Abstract
PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1).Org: The University of Chicago Medicine Center for Advanced Care at Orland Park, Quantum Leap Healthcare Collaborative,
Abstract
A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.Org: H. Lee Moffitt Cancer Center and Research Institute, Regeneron Pharmaceuticals, Inc., Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Correlation of distinct circulating cytokine/chemokine profiles with clinical benefits of Pexa-Vec (thymidine kinase-deactivated vaccinia virus plus GM-CSF) and cemiplimab (REGN2810; anti-PD-1) in metastatic or unresectable renal cell carcinoma (mRCC).Org: Chonnam National University Medical School and Hwasun Hospital, Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonesi University College of Medicine, Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center,
Abstract
A phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L1 ≥50%.Org: University of Tennessee Medical Center, Mid Florida Cancer Centers, Clermont Oncology Center, Emad Ibrahim, MD, Inc., Desert Hematology Oncology Medical Group, Inc.,
Abstract
A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.Org: Institut Català d’Oncologia-IDIBELL, Regeneron Pharmaceutials, Inc.,
Abstract
Overlapping and non-overlapping indications for checkpoint inhibitors in the US.Org: Brigham and Women's Hospital, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center,
Abstract
Initial results from a first-in-human phase 1 study of SNS-101 (pH-selective anti-VISTA antibody) alone or in combination with cemiplimab in patients with advanced solid tumors.Org: West Valley City, San Antonio, TX,
Abstract
A phase 1/2 study of BDC-3042, a novel dectin-2 agonistic antibody, in patients with advanced cancers.Org: Next Oncology Virginia and Virginia Cancer Specialists, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Dana-Farber Cancer Institute, Stanford University School of Medicine,
Abstract
Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.Org: Owkin France, Centre Leon Berad,
Clinical trial
A Phase 2 Peri-Operative Study of Treatment With Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Patients With Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)Status: Not yet recruiting, Estimated PCD: 2026-06-08
Abstract
Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.Org: The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, Henry Ford Cancer Institute, Detroit, MI, START San Antonio, San Antonio, TX, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, MUSC Hollings Cancer Center, Charleston, SC,
Abstract
Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC).Org: Memorial Sloan Kettering Cancer Center,
Abstract
First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer.Org: Stephenson Cancer Center, University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute, Massachusetts General Hospital, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC,
Abstract
Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.Org: Johns Hopkins Kimmel Cancer Center, Regeneron Pharmaceuticals, Inc., Department of Nuclear Medicine Zürich, University Hospital of Zürich, Department of Medical Oncology, Başkent University, High Technology Medical Centre, University Clinic,
Abstract
Cemiplimab for kidney organ transplant recipients with advanced cutaneous squamous cell carcinoma: CONTRAC-1.Org: Dana-Farber Cancer Institute, Tufts Medical Center/Tufts University, Maine Medical Center Research Institute, Brigham and Women's Hospital/Massachusetts General Hospital, Brigham and Women's Faulkner Hospital,
Abstract
Combined pulsed radiotherapy (QUAD shot regimen) with immune checkpoint inhibition (ICI) to enhance immune response for LAHNSCC in patients considered ineligible for curative intent therapy.Org: Grandview Cancer Center, Helen F. Graham Cancer Center and Research Institute, Newark, DE, Thomas Jefferson University Hospital, Christiana Care Health System, Med Onc / Hem Consultants,
Abstract
Phase 2 study of ISA101b (peltopepimut-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy.Org: King's College London, ISA Pharmaceuticals B.V., Gustave Roussy Département d'Organisation du Parcours Patient, Centre Leon Bérard, H. Lee Moffitt Cancer Center & Research Institute,
Abstract
A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.Org: University of Tennessee Medical Center at Knoxville, Orlando Health Cancer Institute, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, St. John's Cancer Institute, Santa Monica, CA,
Abstract
Neoadjuvant immunotherapy in hepatocellular carcinoma: A systematic review and meta-analysis.Org: Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT, UMass Chan Medical School, Shrewsbury, MA,
Abstract
Cemiplimab in first line treatment for locally advanced and metastatic skin squamous cell carcinoma in Slovenia.Org: Institute of Oncology Ljubljana,
Abstract
CemiplimAb-rwlc survivorship and epidemiology (CASE): A prospective study of safety and efficacy of cemiplimab in patients with advanced basal cell carcinoma in a real-world setting.Org: Charleston Oncology, The Melanoma And Skin Cancer Institute, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Department of Hematology and Oncology, Miami Cancer Institute/Baptist Health South Florida, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma.Org: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, Moffitt Cancer Center and Research Institute, Tampa, FL, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, The Univ of Utah, Salt Lake City, UT,
Abstract
Obesity, dyslipidemia, and diabetes as determinants of response to immune checkpoint inhibitors in non-small cell lung cancer.Org: Beth Israel Deaconess Medical Center, Roswell Park Comprehensive Cancer Center, Mount Auburn Hospital, Harvard Medical School, Lahey Hospital and Medical Center, Burlington, MA,
Abstract
Adrenal insufficiency in patients on immune checkpoint inhibitors: An All of Us Data study.Org: Harlem Hospital Center, New York Oncology Hematology PC,
Abstract
A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.Org: Todua Clinic, Tbilisi, Georgia, High Technology Medical Centre, University Clinic, Tbilisi, Georgia, LTD High Technology Hospital Med Center, Batumi, Georgia, Consilium Medullla, Tbilisi, Georgia, LTD TIM Tbilisi Institute of Medicine, Tbilisi, Georgia,
Abstract
Anti-drug antibodies related to CTLA-4, PD-1, or PD-L1 inhibitors across tumour types: A systematic review.Org: Imperial College, University Medical Center Mainz, Mtech Access, Eisai, UCLA Medical Center,
Abstract
How comparable are outcomes for approved PD-1/PD-L1 checkpoint inhibitors (CPI)? A model-informed drug development approach to answer the question.Org: Gilead Sciences, Inc., Foster City, CA, Certara, Inc., Princeton, NJ, Gilead Sciences Inc.,
Abstract
The PRIME-CUT study: A single-arm phase 2 study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center, Spectrum Medical Group, Columbia University Irving Medical Center, New York, NY, USA, Columbia University Medical Center,
Abstract
NEO-CESQ study: Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma.Org: Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, China, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Department of Medical and Surgical Specialties,
Abstract
Immune checkpoint inhibitors in cutaneous squamous cell carcinoma: A systematic review of clinical trials.Org: BronxCare Health System, New York Medical College - Saint Michael's Medical Center, Saint Mary's and Saint Clare's Hospital, Mercy Hospital Fort Smith, Arkansas College of Osteopathic Medicine,
Abstract
Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: Real-world evidence.Org: Princess Margaret Cancer Centre, University Health Network, University of Toronto, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Dermatology,
Product
cemiplimab + placeboProduct
anti PD-1 antibodiesProduct
PD1/L1 antibodyProduct
peltopepimut-S + cemiplimabProduct
anti PD-1 therapyProduct
PD-1 blockadeProduct
anti-PD-1/L1 monotherapyProduct
Single-agent immunotherapyProduct
PD1 therapyProduct
ADT + cemiplimab + docetaxelProduct
PD-1 or CTLA inhibitorsProduct
ubamatamab + cemiplimabProduct
THIO + cemiplimab